56 results about "Obsessive-compulsive disorders" patented technology

The invention discloses an obsessive-compulsive disorder diagnosis system based on brain multi-modal indexes, and belongs to the field of mental diseases. The problem of lack of a cross-modal feature fusion mechanism is solved. The system comprises an electroencephalogram signal acquisition unit used for acquiring an EEG signal of a testee under a preset stimulation normal form and executing preprocessing operation; the brain imaging data acquisition unit is used for synchronously acquiring brain structure imaging data and brain function imaging data of the testee; the multi-modal data fusion unit is used for extracting frequency band power spectrum density characteristics and event-related potential amplitude or incubation period characteristics from the EEG signals; performing standardization processing on the EEG features, the sMRI structural features and the fMRI functional features; integrating modal features by adopting a weighted average fusion algorithm; screening fused feature subsets through a recursive feature elimination method; and the diagnosis model unit is used for inputting the fusion feature vector into a trained SVM classification model and outputting an obsessive-compulsive disorder diagnosis result. Used in the medical field.

The present invention relates to Compound 1 for the use in the treatment of Major Depressive Disorder, Treatment-resistant Depression, Bipolar Depressive Disorder, Depressive Episodes associated with Bipolar disorders, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder, and / or Borderline Personality Disorder, chemical synthesis of Compound 1, polymorphs of Compound 1, and pharmaceutical compositions comprising Compound 1 and / or its polymorphs.

The invention belongs to the technical field of biomedical imaging, and particularly discloses an in-vivo imaging method of an SAPAP3 gene defect disease model, which is characterized in that an effective dose of an S1PR1 receptor targeted radioactive probe is injected into the body of the SAPAP3 gene defect disease model. According to the method, an S1PR1 receptor targeting radioactive probe is utilized, the technical bottleneck that in-vivo and dynamic observation of the S1PR1 receptor cannot be achieved through an existing in-vitro technology is solved, and an indispensable visual tool and a quantitative evaluation means are provided for studying the neurobiological mechanism of related mental diseases such as obsessive-compulsive disorder and accelerating research and development of related drugs.

Compositions and methods for treating autism spectrum disorder, obsessive compulsive disorder or tics with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, are provided. The compositions and methods may be used to improve one or more symptoms of autism spectrum disorder, obsessive compulsive disorder or tics. (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.

A pathway planning apparatus includes a processor configured to plan a pathway for implanting an electrode lead into a brain of a patient, wherein the planned pathway satisfies the following condition: if the electrode lead is implanted into the brain of the patient according to the pathway, the electrode lead is capable of simultaneously making contact with an anterior limb of an internal capsule and a nucleus accumbens in one hemisphere of a brain of the patient. The pathway planned by the pathway planning apparatus enables the electrode lead to simultaneously deliver the electrical stimulation to the anterior limb of the internal capsule and the nucleus accumbens such that a combined electrical stimulation therapy is achieved, which has a better effect of treating diseases such as addictive behaviors, depressive disorders, and obsessive-compulsive disorders.

In alternative embodiments, provided are products of manufacture, including devices and integrated systems, and methods, for reducing error-related negativity (ERN) and anxiety, and for treating or ameliorating Anxiety Disorders such as Generalized Anxiety Disorder (GAD) or Social Anxiety Disorder (SAD) and obsessive-compulsive disorder (OCD).

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

Described are 6-aryl isoindolin-1-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and / or solvate thereof. The invention also relates to the use of the compounds of formula (I) as a medicament, in particular for the prevention or treatment of obsessive-compulsive disorder and related behaviors, including addiction, obsessive-compulsive disorder and dietary disorder, and neurodegenerative diseases, such as Parkinson's disease or Alzheimer's disease.

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

A modified-release tablet dosage form containing tolcapone is disclosed. The tablet dosage form provides a pulsatile, pH-dependent release profile of tolcapone to both the gastric cavity and the small intestine. Methods for treating or preventing a disease selected from transthyretin amyloidosis (ATTR), Parkinson's disease, and obsessive-compulsive disorder using the dosage form are provided.

To provide a treatment support device, a treatment support method, and a program capable of facilitating input by a patient and saving time and effort for creating a symptom list and an anxiety hierarchy table in treatment of obsessive-compulsive disease.SOLUTION: The treatment assistance apparatus 1 includes the symptom information acquisition unit 33 that acquires symptom information, which is information about symptoms, from the patient terminal 2 that receives treatment for obsessive-compulsive disease, the anxiety degree information acquisition unit 34 that acquires anxiety degree information, which is information about the relative degree of anxiety of the patient about the symptoms, from the patient terminal 2, and the information acquisition control unit 32 that receives inputs of the symptom information and the anxiety degree information about the symptoms from the patient terminal 2 in parallel.SELECTED DRAWING: Figure 3

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Protocadherin 19 (PCDH19) RNA in a cell or subject, and in certain instances reducing the amount of PCDH19 protein in a cell or subject. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodevelopmental disease or disorder. Such neurodevelopmental diseases or disorders include PCDH19 Epilepsy. Such symptoms or hallmarks include seizures, cognitive impairment, intellectual disabilities, autism spectrum disorder, behavioral problems, aggression, anxiety, obsessive-compulsive disorder, hyperactivity, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD).

A method of treating, preventing or ameliorating at least one symptom of obsessive compulsive disorder (OCD) in a subject is disclosed. The method comprises a step in which a multistrain probiotic formulation is administered to the subject. The multistrain probiotic formulation includes the bacterial strains Bacillus coagulans, Lactobacillus rhamnosus, Bifidobacterium lactis, Lactobacillus plantarum, Bifidobacterium breve and Bifidobacterium infantis and Glutamine in a concentration range of 100-500 mg.

The application belongs to the technical field of medicines, and relates to an N-H aporphine nitrogen-containing heterocyclic derivative, a preparation method and application thereof.The N-H aporphine nitrogen-containing heterocyclic derivative comprises a compound shown in a general formula M, isomers thereof and pharmaceutically acceptable salts or hydrates thereof.The application introduces a nitrogen-containing heterocyclic ring into an aporphine derivative, and the disclosed N-H aporphine nitrogen-containing heterocyclic derivative can be applied in the preparation of medicines for preventing and / or treating obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes and drug addiction.

The application relates to application of Lactobacillus murinus in preparation of a drug for treating obsessive-compulsive disorder. The application provides application of Lactobacillus murinus in preparation of a drug for treating obsessive-compulsive disorder, two different OCD mouse models are used to systematically evaluate the intervention effect of Lactobacillus murinus on obsessive-compulsive behavior, and the potential molecular mechanism is preliminarily explored. The results show that the intervention of Lactobacillus murinus can effectively improve the anxiety and obsessive-compulsive behavior of OCD model mice. Further mechanism research finds that the intervention effect may be related to the increase of the activity of excitatory neurons in the medial prefrontal cortex (mPFC) of Lactobacillus murinus.

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt and / or solvate thereof. The present invention also relates to the use of the compound of formula (I) as a drug, in particular for preventing or treating compulsive disorders and related behaviors, including addiction, obsessive-compulsive disorders and eating disorders, and neurodegenerative disorders such as Parkinson's disease or Alzheimer's disease.

The invention provides an obsessive-compulsive disorder animal model and a construction method and application thereof, and relates to the technical field of animal models. A construction method of an obsessive-compulsive disorder animal model comprises the following steps: S1, injecting a quantel solution into a rat according to a standard of 0.5 mg / kg, carrying out neck subcutaneous injection twice a week, and continuously injecting for 5 weeks; s2, detecting behavior characteristics of the rats after administration to obtain a basic animal model; and S3, implanting an electrode into the brain of the basic animal model to obtain a target animal model. According to the method, the neurotransmitter activity condition of the corresponding brain region under the disease state can be completely displayed, and an important foundation is laid for exploring the OCD pathogenesis. According to the animal model and the application thereof, the pathophysiological mechanism of OCD and the treatment mechanism of NAc-DBS can be explored from multiple aspects of animal behavioristics, neuroelectrophysiology, histopathology, molecular biology and the like, and a theoretical basis is laid for clarification of OCD pathogenesis and development of new treatment means.

Provided herein are methods and compositions for treating neurological diseases (e.g., neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease, dementia, a tauopathy, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), mild cognitive impairment); psychiatric disorders (e.g., bipolar disorder, schizophrenia, depression, anxiety, post-traumatic stress disorder, obsessive compulsive disorder); inflammation in the central nervous system) using lithium salts, activators that increase the expression or activity of the RE1 silencing transcription factor (REST), or a combination thereof, or in combination with an additional agent.

This invention provides an apophene derivative, its preparation method, and its application. The general formula of the apophene derivative structure described in this invention is shown below: Among them, R 1 C 1 -C 8 alkoxy or hydrogen, R 2 For hydroxyl or hydrogen; R 3 Selected from C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, C 2 -C 10 alkynyl group, C 2 -C 10 alkenyl, halogen, C 1 -C 8 Halogenated, cyano, nitro, or aryl. The use of the 5-hydroxytryptamine 2A receptor agonist and 5-hydroxytryptamine 2C receptor agonist described in this invention in the preparation of medicaments for the prevention and / or treatment of obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes, and drug addiction.

The present disclosure provides a compound of formula (I): JPEG2026506861000048.jpg37170, or a pharmaceutically acceptable salt and / or solvate thereof. The present disclosure also relates to the use of the compounds of formula (I) as pharmaceuticals, in particular for the prevention or treatment of addictions, obsessive-compulsive disorders and related behaviors, including obsessive-compulsive disorders and eating disorders, and neurodegenerative disorders such as Parkinson's disease or Alzheimer's disease.

A pharmaceutical composition for treating obsessive-compulsive disorder is provided. The present invention relates to (1) a pharmaceutical composition comprising a dopamine D1 receptor agonist as an effective ingredient for treating obsessive-compulsive disorder, and / or (2) a pharmaceutical composition comprising a dopamine D1 and D2 receptor stimulator, which is administered in combination with a dopamine D2 receptor inhibitor for the purpose of stimulating the dopamine D1 receptor in the striatum, and / or (3) a pharmaceutical composition comprising a dopamine D2 receptor inhibitor, which is administered in combination with a dopamine D1 and D2 receptor stimulator.

This invention relates to the use of mGluR5 positive allosteric modulators in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, post-traumatic stress disorder, substance use disorder, depression-related aspects of schizophrenia (e.g. negative symptoms and cognitive impairment associated with schizophrenia), obsessive compulsive disorder, an eating disorder, autism spectrum disorder, chemotherapy-related cognitive dysfunction, Parkinson's disease, multiple sclerosis, clinical high risk for psychosis, and attenuated psychosis syndrome in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

This invention relates to a predictive system for the efficacy of tDCS treatment for obsessive-compulsive disorder (OCD) based on EEG. The system includes a data acquisition and processing module for acquiring resting-state EEG data of the subject; a data preprocessing module for filtering the acquired EEG data and removing signals containing artifacts; a data spectrum analysis and processing module for converting the EEG time-domain signal into a frequency-domain signal using Fast Fourier Transform and dividing it into different frequency bands; and an efficacy prediction processing module for determining the predicted efficacy of tDCS treatment based on the comparison between the subject's characteristic curve and the optimal critical point. This invention also relates to a corresponding method, apparatus, processor, and storage medium. The system, method, apparatus, processor, and storage medium of this invention represent the first method for predicting the efficacy of tDCS treatment for OCD based on EEG. The algorithm has high accuracy and helps solve the key problem of difficulty in selecting treatment methods in clinical diagnosis and treatment.

Provided herein are methods for treating psychiatric disorders by gene therapy (e.g. AAV-directed gene therapy) to deliver and express the human SP4 gene in neuronal cells. Treatable psychiatric disorders include schizophrenia, anxiety, obsessive compulsive disorder, or mood disorder.

The invention discloses a machine learning-based obsessive-compulsive disorder subtype classifier and a classification method, and belongs to the field of obsessive-compulsive disorder classification. The problems that an existing machine learning model can only distinguish an OCD patient from a healthy control and lacks unsupervised exploration and treatment response prediction on disease subtypes are solved. Comprising the steps that a data input module collects multi-modal data of a patient suffering from obsessive-compulsive disorder; the preprocessing module performs preprocessing based on voxel and surface morphology measurement on the sMRI data, and eliminates a multi-site data batch effect by using a COMBAT algorithm; the feature selection module is used for screening different brain region features between the obsessive-compulsive disorder group and the healthy control group and carrying out standardization processing; the model construction module is connected with the feature selection module and comprises a supervised classification unit and an unsupervised clustering unit; the prognosis prediction module inputs the subtype labels output by the unsupervised clustering unit and clinical feature data into a logistic regression model, and predicts the individual treatment alleviation probability; and the output module generates a subtype classification result. The method is mainly used in medical field.

The present invention relates to a system and method for managing neurological and psychological disorders, with a specific focus on Obsessive-Compulsive Disorder (OCD). The invention integrates pharmacotherapy, Deep Transcranial Magnetic Stimulation (Deep TMS), and Exposure and Response Prevention (ERP) therapy into a unified framework that addresses the chemical, neurological, and behavioural dimensions of OCD. The system utilizes advanced data analysis and machine learning algorithms to dynamically customize interventions based on patient-specific profiles, ensuring optimal therapeutic efficacy and reduced side effects. The System includes real-time data-driven adjustments, high-intensity engagement protocols, remote monitoring for long-term management, and scalable group therapy capabilities. The system also incorporates advanced neuromodulation technologies and compressed ERP techniques to accelerate behavioural restructuring and neural circuit modulation. By leveraging the synergy between these modalities, the invention provides a holistic and versatile solution for improving patient outcomes, ensuring sustained symptom relief and enhanced quality of life.

Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.

Described are 6-aryl quinazolin-4(3H)-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.